Comparative Pharmacology
Head-to-head clinical analysis: ATELVIA versus BONIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATELVIA versus BONIVA.
ATELVIA vs BONIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Risedronate (the active ingredient in ATELVIA) inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone and inhibiting the mevalonate pathway, which prevents farnesyl pyrophosphate synthase activity, leading to disruption of osteoclast function and induction of apoptosis.
Bisphosphonate that inhibits bone resorption via binding to hydroxyapatite and inhibiting osteoclast activity.
35 mg orally once weekly on the same day each week, taken with at least 240 mL of plain water at least 30 minutes before the first food, beverage, or medication of the day. Do not crush, chew, or suck tablets.
150 mg orally once monthly; 2.5 mg orally once daily also approved but less commonly used. Administer on empty stomach with plain water (6-8 oz) at least 60 minutes before first food, beverage, or other medications. Do not lie down for 60 minutes after administration.
None Documented
None Documented
Terminal elimination half-life is approximately 10 days due to prolonged bone binding and slow release; clinical suppression of bone resorption persists for weeks after discontinuation.
Terminal half-life: 10-60 hours (clinical relevant); long terminal half-life (120-720 hours) due to slow dissociation from bone, supports weekly dosing.
Approximately 50% of absorbed dose excreted renally unchanged; remainder eliminated via biliary/fecal routes. Renal clearance correlates with creatinine clearance.
Renal: ~50-60% unchanged in urine; biliary/fecal: ~40-50% eliminated via feces, primarily as unchanged drug.
Category C
Category C
Bisphosphonate
Bisphosphonate